Designed by expert epidemiologists and infused with our consensus forecasting expertise, Evaluate Epi is an evidence-based source for patient populations that provides the foundation of accurate and robust asset valuations and forecasts. Access detailed patient segmentation data, covering over 530 diseases and over 14,500 sub-populations, to measure the true value of a product.
Access data for 15 therapeutic areas, over 530+ indications and thousands of sub-populations, along with longer forecasting horizons, so you can identify opportunity, model change and understand commercial value.
Understand the complexity of disease segmentation, across multiple regions, split by demographic data, biomarkers, rare diseases and more.
Using the latest research, datasets are constructed using a wide variety of sources and reliable tools and techniques, resulting in a strong and defendable analysis of the epidemiology.
Forecasting, portfolio prioritization and asset valuation decisions require increasingly detailed and reliable epidemiology data. However, drawing confident conclusions about the spread and burden of disease is difficult to achieve. It’s time consuming to gather all the necessary data; and experts are required to evaluate, standardize and consolidate multiple epidemiological data sources into a single body of evidence.
Profile diseases in detail. Customise your view with insights on biomarkers, co-morbidities, line of therapy, disability scales, and age coverage from 0 to 100 in 5-year increments.
Quantify patient populations for clinical trial design selecting disease and conditions across 55 countries.
Conduct budget impact analysis, health economics modeling, and forecast future shifts in patient populations and their effect on sales.
Get in touch with our team to explore the right solutions for your business.
